アブストラクト
| Title | 抗がん薬 |
|---|---|
| Subtitle | 特集 血中濃度の変動要因を見極めよう 悩ましい薬物動態の諸問題 実践編 - 薬剤別マネジメント |
| Authors | 横田隼人 |
| Authors (kana) | |
| Organization | 秋田大学医学部附属病院薬剤部 |
| Journal | 月刊薬事 |
| Volume | 66 |
| Number | 3 |
| Page | 544-550 |
| Year/Month | 2024 / 2 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Points] ●分子標的抗がん薬は, 胃酸分泌抑制薬と併用すると分子標的薬の溶解性が低下し, 血中濃度が低下することがある. ●胃酸分泌抑制薬との相互作用を回避するには, まず胃酸分泌抑制薬の必要性について検討する. ●胃酸分泌抑制薬の中止が難しい場合は, 可能な限りプロトンポンプ阻害薬(PPI)との併用は避けH2受容体拮抗薬への変更を検討する. ●PPIはCYP2C19の基質であり, やむを得ずPPIを併用する場合はCYP2C19遺伝子多型の影響が少ない薬剤を選択する. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Giraud EL, et al : Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update. Lancet Oncol, 24 : e229, 2023
- 2) Sharma M, et al : The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer, 125 : 1155-1162, 2019
- 3) Ohgami M, et al : Effects of Proton Pump Inhibitor Co-administration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer. Ther Drug Monit, 40 : 699-704, 2018
- 4) Aoyama T, et al : Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma. Sci Rep, 13 : 2099, 2023
- 5) Yokota H, et al : Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer. Clin Lung Cancer, 18 : e433-e439, 2017
残りの15件を表示する
- 6) Kletzl H, et al : Effect of gastric pH on erlotinib pharmaco-kinetics in healthy individuals: omeprazole and ranitidine. Anticancer Drugs, 26 : 565-572, 2015
- 7) Yin OQ, et al : Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers. Cancer Chemother Pharmacol, 71 : 219-226, 2013
- 8) Eley T, et al : Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol, 49 : 700-709, 2009
- 9) Soffietti R, et al : Management of brain metastases. J Neurol, 249 : 1357-1369, 2002
- 10) Luo JC, et al : Non-ulcerogenic dose of dexamethasone delays gastric ulcer healing in rats. J Pharmacol Exp Ther, 307 : 692-698, 2003
- 11) 日本緩和医療学会, 他・編 : がん疼痛の薬物療法に関するガイドライン2020年版. 金原出版, 2020
- 12) 日本消化器病学会・編 : 消化性潰瘍診療ガイドライン2020 改訂第3版. 南江堂, 2020
- 13) 日本消化器病学会・編 : 胃食道逆流症(GERD)診療ガイドライン2021 改訂第3版. 南江堂, 2021
- 14) Sugimoto M, et al : Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. Eur J Clin Pharmacol, 70 : 1073-1078, 2014
- 15) Kubota T, et al : Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther, 60 : 661-666, 1996
- 16) Kita T, et al : Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull, 26 : 386-390, 2003
- 17) Li XQ, et al : Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos, 32 : 821-827, 2004
- 18) Sakurai Y, et al : Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther, 42 : 719-730, 2015
- 19) van Leeuwen RW, et al : Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol, 34 : 1309-1314, 2016
- 20) Zhao YY, et al : The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Med Oncol, 28 : 697-702, 2011
